SCHEMBL2213848

SCHEMBL2213848

CCC(CO)NC(=O)c1cccc(N(Cc2ccc(Cl)cc2)S(=O)(=O)c2ccn(C)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 6/20 0.42
DYRK2 Q92630 6/20 0.42
DYRK1B Q9Y463 6/20 0.42
DYRK3 O43781 5/20 0.42
LMNA P02545 4/20 0.39
HTT P42858 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CDK5 Q00535 1/20 0.38
CDK5R1 Q15078 1/20 0.38
DGAT2 Q96PD7 1/20 0.37
POLB P06746 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL327188 0.93 DYRK1A (0.38) DYRK1ADYRK2DYRK1BDYRK3LMNA
SCHEMBL2212260 0.90 LMNA (0.40) LMNAHTTMEN1KMT2ADGAT2
SCHEMBL303432 0.89 LMNA (0.42) LMNAHTTMEN1KMT2APOLB
SCHEMBL303301 0.86 MEN1 (0.41) LMNAHTTMEN1KMT2APOLB
SCHEMBL2211916 0.86 MEN1 (0.42) LMNAMEN1KMT2APOLBALDH1A1
SCHEMBL304312 0.85 KMT2A (0.40) LMNAMEN1KMT2APOLBALDH1A1
SCHEMBL3377133 0.83 MEN1 (0.39) LMNAMEN1KMT2ADGAT2POLB
SCHEMBL2214180 0.83 MEN1 (0.54) LMNAMEN1KMT2APOLBALDH1A1
SCHEMBL2214837 0.82 MEN1 (0.44) MEN1KMT2AALDH1A1
SCHEMBL303882 0.82 KMT2A (0.40) LMNAHTTMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US claimed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
EP-2342177-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-07-13 EP disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023448-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 DYRK1A 2308/4885DYRK2 2363/4885DYRK1B 1758/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 DYRK1A 2759/4885DYRK2 2756/4885DYRK1B 2320/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 DYRK1A 2308/4885DYRK2 2363/4885DYRK1B 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.